RNU6-1223P

Across TCGA pan-cancer cohorts, RNU6-1223P RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RNU6-1223P’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RNU6-1223P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-1223P is over-expressed in tumor.

BLCA, READ, and COAD are the cancer types where RNU6-1223P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1223P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.709	.005	6	view →
READ	All	III,IV	+2.145	.001	5	view →
COAD	Male	All	+1.076	<.001	5	view →
LUSC	All	All	+0.687	<.001	5	view →
LIHC	All	All	+0.201	<.001	5	view →
CHOL	All	All	+1.477	.001	4	view →
LUAD	All	All	+0.380	.010	4	view →
STAD	All	II,III,IV	+0.450	.024	3	view →
PRAD	All	All	+0.410	.002	2	view →
ESCA	All	All	+0.695	.033	1	view →
HNSC	All	II,III,IV	+0.221	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RNU6-1223P–BLCA

Open the BLCA breakdown →